BPEA EQT to acquire a majority stake in Indira IVF
The controlling stake will be acquired from TA Associates and the Companys founders, Dr. Ajay Murdia, Dr. Kshitiz Murdia, and Dr. Nitiz Murdia, who will retain a significant minority stake and continue to lead the company.
Sweden-headquartered investment firm EQT has announced that its subsidiary BPEA Private Equity Fund VIII ("BPEA EQT") has agreed to acquire a controlling stake in Indira IVF, India’s largest fertility clinic chain.
The controlling stake will be acquired from TA Associates and the Company’s founders, Dr. Ajay Murdia, Dr. Kshitiz Murdia, and Dr. Nitiz Murdia, who will retain a significant minority stake and continue to lead the company.
With this transaction, BPEA Private Equity Fund VIII is expected to be 35 per cent to 40 per cent invested in the company.
"This investment aligns with EQT’s commitment to investing in companies that address critical societal needs and have the potential to impact people's lives for the better.... We couldn’t be prouder to support such an important mission, and we look forward to partnering with Indira IVF and the Murdia family on its next stage of growth," said Jimmy Mahtani, Partner and Co-Head of BPEA EQT India.
"BPEA EQT is one of the largest healthcare investors globally and has a deep understanding of the IVF sector.... I am delighted to have a like-minded partner in BPEA EQT who shares our purpose, and we are ready to scale the Indira IVF platform to the next level," said Dr. Kshitiz Murdia, CEO of Indira IVF.
Indira IVF was founded by Dr. Ajay Murdia in 1988 and has since scaled from a single clinic to a nationwide network spanning 116 centres across 20 states in India.
Catch the latest stock market updates here. For all other news related to business, politics, tech, sports, and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.